Table 3.
Baseline pretreatment variables based on treatment outcome (SVR) at univariate and multivariate analyses.
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| SVR | Non-SVR | OR 95% CI | P | OR 95% CI | P | ||
| Number of patients | 26 | 49 | |||||
|
| |||||||
| Age (median; range) | 48 (26–67) | 49 (31–67) | 1.07 (1.02–1.12) | 0.008 | 1.26 (0.99–1.60) | 0.051 | |
| Sex (M/F) | 16/10 | 29/20 | 0.91 (0.34–2.4) | 0.84 | |||
| BMI (median; range) | 22.7 (19.4–29.1) | 24.2 (21.3–29.6) | 1.33 (1.07–1.66) | 0.01 | 1.05 (1.00–1.11) | 0.041 | |
| Fasting glucose (median; range) | 4.86 (2.41–6.23) | 5.1 (2.2–6.88) | 1.16 (0.76–1.79) | 0.49 | |||
| Fasting insulin (median; range) | 8.0 (1.41–24.1) | 8.9 (2.90–33.1) | 0.98 (0.93–1.04) | 0.58 | |||
| HOMA-IR (median; range) | 1.93 (0.3–10.3) | 2.25 (0.3–10.5) | 0.95 (0.77–1.18) | 0.65 | |||
| Leptin (median; range) | 6.3 (2.2–29.2) | 15.4 (3–55) | 1.01 (0.96–1.05) | 0.89 | |||
| Adiponectin (median; range) | 12.2 (4.5–23.3) | 17.05 (7.1–36.1) | 1.02 (0.94–1.10) | 0.67 | |||